Edoxaban in Peripheral Arterial Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

Also called NCT01802775

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 203 participants (enrolled count) (from the registry)
Sponsor
  • Daiichi Sankyo Registry lists this organization as the lead sponsor
  • UMC Utrecht Registry lists this organization as a collaborator
Registry
  • NCT NCT01802775
  • EudraCT 2012-003009-88
Other papers using this trial's data
  • Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2018-04 DOI, PubMed 29552984, PMC5862321 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Germany, Israel, Netherlands, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01802775. Randomized; no masking; primary purpose treatment. Start 2013-02-06 (actual); primary completion 2014-12-03 (actual). Results posted on 2018-01-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edoxaban in Peripheral Arterial Disease
Acronym
ePAD
Condition
Peripheral Arterial Disease
Intervention (Drug)
edoxaban
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Aspirin
Lead sponsor
Daiichi Sankyo (class: industry)
Collaborator
UMC Utrecht (class: other)

Record details

Record id
cardio:ct-nct01802775
Content hash
41aa659d65e9b0d701f904479122bcb8638f6e85f74558bdcf93e8345a34aff6